💊 BioMarin Restructures, Biogen and AbbVie Decline, While BioNTech Surges Ahead with Promising Cancer Trials | Biotech Sector Insights
Gilead Sciences is set to present new data on its cancer treatment Trodelvy at the upcoming IASLC 2024 World Conference on Lung Cancer, focusing on various studies related to lung cancer, although the drug has not yet received regulatory approval for these indications.
Welcome to the MarketReader Minute.
Below are AI-generated insights on moves in the health care/biotechnology sector, powered by MarketReader technology.
Thursday, September 5
IBB [-0.8%]
The iShares Biotechnology ETF (IBB) has experienced a decline of 0.6% since Wednesday. Key holdings contributing to this downturn include Vertex Pharmaceuticals (VRTX), Amgen (AMGN), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), and Biogen (BIIB), all of which reported negative returns. Notably, Gilead Sciences is set to present new data on its cancer treatment Trodelvy at the upcoming IASLC 2024 World Conference on Lung Cancer, focusing on various studies related to lung cancer, although the drug has not yet received regulatory approval for these indications. In a broader market context, the Dow Jones Index has decreased by 0.12%, suggesting a potential correlation with the price movement of IBB.